Pomerantz LLP is investigating Banc of California and some of its executives for potential securities fraud following the company's Q2 2026 report, which showed a $251.3 million net loss, far below expectations. The loss was linked to a balance-sheet restructuring involving the sale of $2.3 billion in lower-yielding securities and $827 million in commercial real estate loans. Banc of California's stock dropped over 12% after the announcement. The investigation could lead to a class action lawsuit if wrongdoing is found.
Scotiabank increased its price target for Palo Alto Networks to $430, suggesting a 13% upside from current levels, following a 30% surge in shares after strong Q3 results. The cybersecurity firm is expected to deliver robust Q4 performance and signif...
Fiserv faces a downgrade from Cantor Fitzgerald with a new price target of $53, down nearly 17% from its recent price of $63.80. The company cut its 2026 guidance, expecting flat to slightly negative organic growth and a 14.2% drop in earnings per sh...
BioMarin Pharmaceutical Inc. saw its stock gain momentum after Jefferies raised its price target to $105, signaling strong confidence in the biotech firm. The company secured new revenue streams through a patent settlement with Ascendis Pharma, earni...
Aehr Test Systems' CEO sold shares worth $5.2 million following a remarkable 564% increase in the company's stock price. This significant sale highlights the CEO capitalizing on the stock's strong rally. Investors may view this move as a signal about...
Zoomd Technologies Ltd. reported a second-quarter EPS of $0.01, surpassing analyst estimates of $0.0038, signaling better-than-expected profitability. Although quarterly revenue was $7.67 million, slightly below the $8.41 million forecast, the compan...
